STAT+: At JPM, Verve details plot to take genome editing mainstream

STAT sat down with Verve Therapeutics CEO Sekar Kathiresan at #JPM24 to dig deeper into the company’s grand plans to take genome editing mainstream.
Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks